XML 80 R43.htm IDEA: XBRL DOCUMENT
v3.21.2

Equity-based compensation (Tables) | 6 Months Ended | 12 Months Ended
--- | --- | ---
Jul. 03, 2021 | Dec. 31, 2020
Schedule of Nonvested Restricted Stock Units Activity | summary of the RSU award activity for the six months ended July 3, 2021 is as follows (number of units in thousands):
|  | Number of units |  |  | Weighted- average grant- date fair value per unit |
Outstanding at December 31, 2020 |  |  | — |  |  | $ | — |
Granted |  |  | 945 |  |  |  | 14.38 |
Outstanding at April 3, 2021 |  |  | 945 |  |  |  | 14.38 |
Granted |  |  | 2 |  |  |  | 14.90 |
Forfeited/canceled |  |  | (4 | ) |  |  | 13.53 |
Outstanding at July 3, 2021 |  |  | 943 |  |  | $ | 14.38 |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions | A summary of the Company’s assumptions used in determining the fair value of the stock options granted during the six months ended July 3, 2021 is shown in the following table.
Risk-free interest rate |  |  | 0.59% - 1.19% |
Expected dividend yield |  |  | —% |
Expected stock price volatility |  |  | 33.1% - 33.5% |
Expected life of stock options |  |  | 5.75 - 6.25 |
Weighted-average fair value of stock options granted |  |  | $4.21 - 5.29 |
Schedule of Stock Options Roll Forward | A summary of stock option activity is as follows for the six months ended July 3, 2021 (number of options in thousands):
|  | Number of options |  |  | Weighted- average exercise price |  |  | Weighted average remaining contractual term |
Outstanding at December 31, 2020 |  |  | — |  |  | $ | — |  |  |  |  |
Granted |  |  | 4,621 |  |  |  | 13.03 |  |  |  |  |
Outstanding at April 3, 2021 |  |  | 4,621 |  |  |  | 13.03 |  |  |  |  |
Granted |  |  | 4 |  |  |  | 14.90 |  |  |  |  |
Outstanding at July 3, 2021 |  |  | 4,625 |  |  |  | 13.03 |  |  |  | 3.3 years |
Bio Ventus LLC [Member] |  |
Summary of Phantom Plan Award activity |  | A summary of the award activity of the Phantom Plan for the year ended December 31, 2020 is as follows (number of awards in thousands):
|  | 2012 Phantom Units |  |  | 2015 Phantom Units |
(awards in thousands) |  | Number of awards |  |  | Weighted average grant-date fair value |  |  | Number of awards |  |  | Weighted average grant-date fair value |
Outstanding at December 31, 2019 |  |  | 658 |  |  | $ | 5.72 |  |  |  | 1,139 |  |  | $ | 10.24 |
Granted |  |  | — |  |  | $ | — |  |  |  | 553 |  |  | $ | 10.29 |
Converted to cash |  |  | — |  |  | $ | — |  |  |  | (146 | ) |  | $ | 6.45 |
Forfeited |  |  | — |  |  | $ | — |  |  |  | (124 | ) |  | $ | 12.98 |
Outstanding at December 31, 2020 |  |  | 658 |  |  | $ | 5.72 |  |  |  | 1,422 |  |  | $ | 10.41 |
Awards vested at December 31, 2020 |  |  | 658 |  |  | $ | 5.72 |  |  |  | 495 |  |  | $ | 8.15 |
Bio Ventus LLC [Member] | Other Phantom Unit [Member] |  |
Summary of Phantom Plan Award activity |  |
|  | 2012 Phantom Units |  |  | 2015 Phantom Units |
(awards in thousands) |  | Number of awards |  |  | Weighted average grant-date fair value |  |  | Number of awards |  |  | Weighted average grant-date fair value |
Nonvested at December 31, 2019 |  |  | 2 |  |  | $ | 10.01 |  |  |  | 667 |  |  | $ | 12.71 |
Vested during 2020 |  |  | 2 |  |  | $ | 10.01 |  |  |  | 147 |  |  | $ | 10.81 |
Nonvested at December 31, 2020 |  |  | — |  |  | $ | — |  |  |  | 927 |  |  | $ | 11.62 |

X
- Definition Share based compensation phantom plan shares award unvested activity. + References No definition available. + Details
Name: | bvs_ShareBasedCompensationPhantomPlanSharesAwardUnvestedActivityTableTextBlock
Namespace Prefix: | bvs_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the changes in outstanding nonvested restricted stock units. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(2) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details
Name: | us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details
Name: | us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the change in stock options. + References No definition available. + Details
Name: | us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | dei_LegalEntityAxis=bvs_BioVentusLlcMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AwardTypeAxis=bvs_OtherPhantomUnitMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |